| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LCN15 |
| Uniprot No | Q6UWW0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-184aa |
| 氨基酸序列 | EVLLQPDFNA EKFSGLWYVV SMASDCRVFL GKKDHLSMST RAIRPTEEGG LHVHMEFPGA DGCNQVDAEY LKVGSEGHFR VPALGYLDVR IVDTDYSSFA VLYIYKELEG ALSTMVQLYS RTQDVSPQAL KSFQDFYPTL GLPKDMMVML PQSDACNPES KEAP |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是模拟生成的关于LCN15重组蛋白的参考文献示例(实际文献需通过学术数据库验证)：
1. **《重组人LCN15蛋白的表达及其在炎症反应中的功能研究》**
*作者：Zhang Y, et al.*
摘要：本研究通过原核表达系统成功制备了重组LCN15蛋白，并发现其能够抑制巨噬细胞中NF-κB信号通路的激活，提示LCN15可能作为炎症调控分子发挥作用。
2. **《LCN15重组蛋白的结构解析与配体结合特性》**
*作者：Wang L, et al.*
摘要：利用X射线晶体学阐明了LCN15重组蛋白的三维结构，发现其疏水腔可特异性结合视黄酸类分子，为开发靶向药物载体提供理论依据。
3. **《LCN15重组蛋白在代谢综合征中的潜在生物标志物价值》**
*作者：Kim S, et al.*
摘要：通过ELISA检测发现肥胖患者血清LCN15水平显著升高，重组蛋白体外实验证实其与脂肪酸代谢相关受体存在相互作用，提示其代谢调控潜力。
4. **《基于昆虫细胞系统的LCN15重组蛋白高效表达与纯化》**
*作者：Müller J, et al.*
摘要：优化了杆状病毒-昆虫细胞表达体系，获得高纯度LCN15重组蛋白，并验证其稳定性可用于体外诊断试剂开发。
---
**提示**：以上文献为模拟生成，实际研究需查询PubMed/Google Scholar等平台(检索关键词：recombinant LCN15 protein/lipocalin 15 expression)。若研究领域较新，可扩展检索相关脂质运载蛋白家族(如LCN2/NGAL)的文献作为参考。
LCN15 (Lipocalin-15) is a member of the lipocalin protein family, a diverse group of small secretory proteins characterized by a conserved eight-stranded β-barrel structure that facilitates ligand binding. Lipocalins are involved in various biological processes, including lipid transport, cell signaling, and immune regulation. While the exact physiological role of LCN15 remains less characterized compared to well-studied lipocalins like neutrophil gelatinase-associated lipocalin (NGAL), emerging evidence suggests its potential involvement in metabolic regulation, cellular homeostasis, and inflammatory responses. Sequence homology analyses indicate LCN15 shares structural motifs with other lipocalins, implying a capacity to interact with hydrophobic molecules such as steroids, retinoids, or fatty acids.
Recombinant LCN15 protein is produced using biotechnological platforms (e.g., bacterial, yeast, or mammalian expression systems) to enable large-scale, purified protein for functional studies. Its recombinant form allows researchers to investigate binding partners, signaling pathways, and therapeutic applications without interference from native biological matrices. Recent studies have explored LCN15's expression patterns in tissues like the liver, adipose, and reproductive organs, hinting at tissue-specific roles. Notably, some research links LCN15 to metabolic disorders and cancer progression, though mechanistic insights remain limited.
The development of recombinant LCN15 has accelerated structural studies, including crystallography and ligand-binding assays, to decipher its 3D conformation and interaction networks. Potential applications span drug delivery (exploiting lipocalins' cargo-carrying ability), diagnostic biomarkers, and targeted therapies. However, comprehensive functional validation and in vivo models are needed to clarify its biological significance and translational potential. As a relatively understudied lipocalin, LCN15 represents an emerging focus for both basic research and biotechnological innovation.
×
